A prospective, Randomized, clinical trial to compare the efficacy and tolerability of pantoproazole in the treatment of Duodenal ulcer
Article Sidebar
Main Article Content
Abstract
Pantoproazole is a new substituted benzimidazole which inhibits gasric H+, K+ ATPase. In this prospeceive randomized clinical trial, pantoprazole 40mg once daily was compared with omeprazole 20mg once daily in the treatment of duodenal ulcer. Endoscopy was repeated after 2 weeks of treatment,. The primary aim was ulcer healing. Unhealed patients were given further 2 weeks of treatment and endoscopy performed at the end. After 2 weeks, 40/50(80%) patients in the pantoprazole group and 26/50(52%) patients in the omeprazole group had healed completely (p<0.05). After 4 weeks, 47/50(94%) patients in the pantoprazole group and 39/50 (78%) patients in the omeprazole group had healed completely (p<0.05). Both treatment were well tolereated. We conclude that pantoprazole is more effective than omemprazole in the treatment of duodenal ulcers.
Article Details
How to Cite
1.
Farooqi JI, Farooqi RJ. A prospective, Randomized, clinical trial to compare the efficacy and tolerability of pantoproazole in the treatment of Duodenal ulcer. J Postgrad Med Inst [Internet]. 2011 Sep. 9 [cited 2024 Nov. 21];13(1). Available from: https://jpmi.org.pk/index.php/jpmi/article/view/633
Issue
Section
Original Article
Work published in JPMI is licensed under a
Creative Commons Attribution-NonCommercial 2.0 Generic License.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.